Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. (4th November 2015)

• Record Type: Journal Article
• Authors: Sznol, Mario; Fishman, Mayer; Escudier, Bernard; McDermott, David F; Kluger, Harriet; Stadler, Walter M; Perez-Gracia, Jose; McNeel, Douglas G; Curti, Brendan D; Harrison, Michael R; Plimack, Elizabeth R; Appleman, Leonard; Fong, Lawrence; Drake, Charles G; Young, Tina C; Chasalow, Scott D; Ross-MacDonald, Petra; Simon, Jason S; Walker, Dana; Choueiri, Toni K
• Is Part Of: Journal for immunotherapy of cancer. Volume 3(2015)Supplement 2
• Publication Date: 2015-11-04
• Subjects: Overall Survival -- Ipilimumab -- Metastatic Renal Cell Carcinoma -- Immune Checkpoint -- Longe Overall Survival; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1186/2051-1426-3-S2-P197
• Languages: English
• ISSNs: 2051-1426